Search

Displaying results 2081 - 2090 of 10000 in total
  1. Drug

    Loteprednol etabonate

    go.drugbank.com/drugs/DB14596
    Approved

    It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes … approved include Kala Pharmaceutical's Inveltys - the first twice-daily (BID) ocular corticosteroid approved for this indication, designed specifically to enhance patient compliance and simplified dosing compared

    Mixtures: TOBRALOT 5 MG+3 MG/ML GÖZ DAMLASI, SÜSPANSİYON, 1 ADET, ZYLET OFTALMIK SUSPANSIYON, 2.5 MLProducts: LOTEMAX 5MG/ML GÖZ DAMLASI, SÜSPANSİYON, 5 ML, VISIONFREE® X 5 ML
  2. Drug

    Pegaspargase

    go.drugbank.com/drugs/DB00059
    ApprovedInvestigational

    [A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927] … However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.

    Categories: Compounds used in a research, industrial, or household settingProducts: ONCASPAR® 750 U/ML POLVO PARA SOLUCIÓN INYECTABLE, ONCASPAR POWDER FOR SOLUTION FOR INJECTION/INFUSION 750 U/ML
  3. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    MRD) greater than or equal to 0.1% in adults and children. … [L44311] Full approval for this indication was granted in June 2023.

    Products: BLINCYTO® 38.5 MCG/VIAL, BLINCYTO POWDER FOR INFUSION 35 MCG/VIAL
  4. Pathway

    Pyruvate Dehydrogenase Complex Deficiency

    smpdb.ca/view/SMP0000212
    Disease

    PDHA1 encodes the pyruvate dehydrogenase complex (PDC) a critical complex that converts pyruvate from glycolysis to acetyl CoA for the citric acid cycle. … Pyruvate dehydrogenase complex deficiency results from a mutation in the E1-alpha polypeptide gene (PDHA1).

    Drugs: Pyruvic acid · Biotin · Adenosine phosphate · Glutathione · NADH · ATP +13 more
    Enzymes: Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial
  5. Pathway

    Mitochondrial Complex II Deficiency

    smpdb.ca/view/SMP0000548
    Disease

    Interestingly, complex II deficiency gene mutation carriers may be at an increased risk for certain cancers. … Because complex II is found in the mitochondria, CII deficiency is technically considered a mitochondrial disease.

    Drugs: Pyruvic acid · Biotin · Succinic acid · NADH · ATP · Magnesium cation +4 more
    Enzymes: Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial, Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial
  6. Pathway

    Copper gluconate Drug Metabolism

    smpdb.ca/view/SMP0130548
    Metabolic

    Copper gluconate passes through the liver and is then excreted from the body mainly through the kidney. … Copper gluconate is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis.

    Drugs: Copper gluconate
  7. Drug

    Pirenoxine

    go.drugbank.com/drugs/DB15945
    Investigational

    Products: KARY UNI OPHTHALMIC SUSPENSION 0.05 mg/ml
  8. Drug

    Oxytocin

    go.drugbank.com/drugs/DB00107
    ApprovedInvestigationalVet approved

    Sir Henry H. Dale first identified oxytocin and its uterine contractile properties in 1906. … [A229008] It plays an important role in pair bonding, social cognition and functioning, and even fear conditioning.

    Products: Oxyla 10 IU/mL Injection, Oxytocin Inj 10unit/ml USP
  9. Drug

    Potassium acetate

    go.drugbank.com/drugs/DB14498
    Approved

    Mixtures: NUMETA PED G16 % E İNFÜZYONLUK EMÜLSİYON, 500 ML, NUTRIFLEX LIPID PLUS INFUZYONLUK EMULSIYON, 2500 MLProducts: DBL POTASSIUM ACETATE CONCENTRATED INJECTION 2.45 g/5 ml, Potassium Acetate Inj 2meq/ml
  10. Drug

    Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10788
    ApprovedInvestigational

    Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) is a vaccine that contains inactivated acellular pertussis antigen that is isolated from Bordetella pertussis culture.

    Mixtures: Repevax Injektionssuspension in einer Fertigspritze, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGEProducts: PERTAGEN® SUSPENSION FOR INJECTION 0.5 ML/DOSE